- Home
- MXE vs RADX Comparison
MXE vs RADX Comparison
Compare MXE & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXE
- RADX
- Stock Information
- Founded
- MXE 1990
- RADX 2021
- Country
- MXE United States
- RADX Australia
- Employees
- MXE N/A
- RADX N/A
- Industry
- MXE Finance Companies
- RADX
- Sector
- MXE Finance
- RADX
- Exchange
- MXE Nasdaq
- RADX NYSE
- Market Cap
- MXE 38.7M
- RADX 31.8M
- IPO Year
- MXE N/A
- RADX N/A
- Fundamental
- Price
- MXE $9.12
- RADX $4.30
- Analyst Decision
- MXE
- RADX Strong Buy
- Analyst Count
- MXE 0
- RADX 1
- Target Price
- MXE N/A
- RADX $15.00
- AVG Volume (30 Days)
- MXE 5.8K
- RADX 40.0K
- Earning Date
- MXE 01-01-0001
- RADX 02-26-2025
- Dividend Yield
- MXE 2.66%
- RADX N/A
- EPS Growth
- MXE N/A
- RADX N/A
- EPS
- MXE N/A
- RADX N/A
- Revenue
- MXE N/A
- RADX $204,609.00
- Revenue This Year
- MXE N/A
- RADX N/A
- Revenue Next Year
- MXE N/A
- RADX N/A
- P/E Ratio
- MXE N/A
- RADX N/A
- Revenue Growth
- MXE N/A
- RADX N/A
- 52 Week Low
- MXE $8.40
- RADX $3.50
- 52 Week High
- MXE $11.51
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- MXE 60.62
- RADX N/A
- Support Level
- MXE $8.62
- RADX N/A
- Resistance Level
- MXE $8.77
- RADX N/A
- Average True Range (ATR)
- MXE 0.18
- RADX 0.00
- MACD
- MXE 0.04
- RADX 0.00
- Stochastic Oscillator
- MXE 91.49
- RADX 0.00
About MXE Mexico Equity and Income Fund Inc. (The)
Mexico Equity and Income Fund Inc is a closed-end, non-diversified management investment company. It maintains an investment objective of long-term capital appreciation through investments in securities, primarily equity, listed on the Mexican Stock Exchange. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.